

CHUCK SUN

Partner·Shanghai

+86 21 2208 1024

chuck.sun@fangdalaw.com

PRACTICE AREA

MR. SUN SPECIALIZES IN M&A, PRIVATE EQUITY, VENTURE CAPITAL, OUTBOUND INVESTMENT AND FOREIGN DIRECT INVESTMENT.

Education

- University of Montreal, Faculty of Law, LL.M.
- East China University of Political Science and Law, LL.B.

Professional Qualification

- Admitted to practice in the PRC

Professional Background

- Mr. Sun joined Fangda in 2014. Before joining the firm, he worked at a leading PRC boutique M&A law firm for several years.

REPRESENTATIVE MATTERS AND CASES

Chuck has advised several PRC clients in their outbound investments in semiconductor, renewable energy (carbon neutrality) and automobile parts sectors. Recent transactions include:

- Represented a buyer consortium led by Shanghai Wanye Enterprises (SSE: 600641), in its approximately US$398 million acquisition of Compart Systems from Platinum Equity;
- Represented a buyer consortium led by Envision Group, one of the 50 smartest companies in 2019 as selected by MIT Technology Review, as the global deal counsel, in its simultaneous leveraged acquisition of 75% of electric battery operations and production facilities (located in Japan, UK and US) from Nissan Motor Co., Ltd. (Nissan), and 100% of NEC Energy Devices, Ltd. (located in Japan) from NEC Corporation, its subsequent formation of a resulting joint venture (Envision AESC) with Nissan, and the equity financing of Envision AESC from Primavera, Sequoia and Envision Group;
- Represented Weifu High-Technology Group Co., Ltd. (SZSE: 000581) in its approximately EUR60 million acquisition of the entire vacuum and hydraulic pump business in Italy and China from Robert Bosch GmbH.

Chuck has advised multinational clients and strategic investors in their acquisitions, joint ventures and investments in interactive entertainment, automobile parts, consumer, semiconductor, logistics, healthcare and hospitality sectors. Recent transactions include:

- Represented Zynga Inc. (now part of Take-Two (NASDAQ: TTWO)), a global leader in interactive entertainment, as its PRC counsel in its acquisition of StarLark, a developer of the fast-growing and second largest mobile golf game in the world, Golf Rival, from Betta Games for a total purchase price of approximately US$525 million in cash and stock;
- Represented Weifu High-Technology Group Co., Ltd. (SZSE: 000581) in its formation of a RMB 440 million joint venture with Bosch Rexroth;
- Represented Nayuki Holdings Limited (HKEX:2150) in its RMB525 million acquisition of the majority stake of LELECHA;
- Represented FrieslandCampina in its sale of an infant-formula factory in China to Yili Group (SSE：600887);
- Represented LANXESS in its sale of Urethane Systems business to Japanese UBE Corporation for EUR460

million;

- Represented Swire Beverage, a subsidiary of Swire Pacific (HKEX: 00019), in its acquisition of equity interests in the bottling operations from The Coca-Cola Company;
- Represented a buyer consortium led by Standard Chartered Private Equity (now Affirma Capital) in its leveraged buyout of Siyanli, a nationwide high-end beauty franchise business, for more than US$200 million, its trade sale of majority interests in Siyanli to a group of private equity investors and minority interests in Siyanli to CHJ Jewelry (SZSE: 002345) in a share swap (aborted) and its trade sale to MBK Partners;
- Represented PSA (now merged into Stellantis) in its various joint-venture business in China, including a potential alliance with a leading PRC auto manufacturer; and the PRC aspects of its global merger with FCA;
- Represented Paccar Inc. in its contemplated investment into a leading heavy-duty vehicle company in China;
- Represented PDSTI (Shanghai Pudong Science And Technology Investment Co., Ltd.) and Shanghai Semiconductor Equipment Material Industry Investment Fund in their several outbound investments, Sino-foreign joint venture formation and minority investments in semiconductor sector;
- Represented Cainiao Network (the logistics arm of Alibaba Group) in its strategic investments in Shanghai KXTX Supply Chain and its approximately US$200 million strategic investments in Baotong Inc. (the logistics arm of Baozun Inc. (NASDAQ: BZUN and HKEX: 9991);
- Represented Alibaba's DingTalk in its acquisition of "Wolai", a collaborative office start-up;
- Represented AstraZeneca in its granting of exclusive commercialization rights to Plendil in China market to China Medical System for an upfront fee of US$310 million and ongoing economic sharing;
- Represented Fresenius in its acquisition of a liquid and dry hemodialysis concentrate producer;
- Represented an investor consortium including The Carlyle Group, FountainVest, Fosun and Primavera Capital in the "going private" and back-door listing transaction of Focus Media;
- Other multinational clients include Blackrock, Carl Zeiss, Chevron Corporation, Danaher, Festool GmbH, Humanetics Group, SK Global Chemical and Vale.

Chuck has extensive experience in advising private equity funds and strategic investors in their investments in TMT (Technology, Media, and, Telecom) sectors. Recent transactions include:

- Represented Alibaba (including Alibaba Group, Alibaba Cloud and AIDC) in their US$1 billion investments into AIGC companies, including MiniMax, 01.AI;
- Represented MBK Partners in its approx. USD286 million investment (together with Mirae Asset Daewoo) into CJ CGV, a leading South Korea's cinema chain;
- Represented Alibaba Group in its more than RMB3 billion investment in China Media Capital and its follow-on investments;
- Represented Alibaba Group and Yunfeng Capital in their more than $700 million investment in NetEase Cloud Music;
- Represented Alibaba Group in investment into Suning Sports;
- Represented Alibaba Group in investment into H Visions, a leading intelligent manufacturing solutions provider;
- Represented Alibaba Group in its joint venture formation with SAIC Motor and the formation of Banma Network Technology, a unicorn provides intelligent automobile operating system, intelligent automobile solutions and digital transportation solutions;
- Represented Boyu Capital and 58.com in their investment in Vanke Service (the property management arm of Vanke Group);
- Represented Yunfeng in its Series B investment in YITU Technology (an AI company), its Series A investment in Didi Freight (the freight logistics arm of Didi), its Series Pre-B investment in X-Epic (an EDA design house) and investment in QST (a MEMS solutions provider);
- Represented CR-CCT Fund as the lead investor in its Series A-2 investment in Aibee (a high-tech company focusing on the digitalization and intelligentization of offline space);
- Represented Ant Financial, Hundsun Electronics and China National Investment & Guaranty Corporation in

their joint establishment of a financial assets exchange;

- Represented Evonik VC in its investment in Haizhou New Materials (a few-layer graphene powder supplier of BYD);
- Represented Yunqi Partners in its Series Seed/Series A investments in Space (an auto driving system developer), DCM360 (a smart robotics company), Openverse (a digital intelligent collaboration solutions provider), and Gooosun (an electromechanical new energy solutions provider);
- Represented Next Engine (an Internet of Vehicles company) in its Series A equity financing from Tencent and follow-on equity financings.

Chuck has extensive experience in advising private equity funds in their investments in healthcare sector. Recent transactions include:

- Represented Yunfeng Capital in its more than RMB2.4 billion investment in Meinian Onehealth Healthcare (SZSE: 002044);
- Represented Hillhouse as the lead investor in its Series A investment in Scivita Medical (a medical device company that provides minimally invasive diagnosis and treatment solutions);
- Represented Hillhouse as the lead investor in its Series B investment in Just Biotherapeutics (now merged into Transcenta and listed on HKSE: 6628) and other biopharmaceutical companies;
- Represented Loyal Valley Capital as the lead investor in its Series B investment in Arctic Vision (an ophthalmic biotech company) and its Series C investment in Sciwind (a clinical-stage biopharmaceutical company);
- Represented LAV (a global biomedical venture capital firm, originally a corporate venture subsidiary of Eli Lilly) in investing in a start-up focused on the research, development, manufacturing, and commercialization of innovative gene therapies for ophthalmology;
- Represented a buyer consortium led by China Life Healthcare Fund and SDIC Fund, in a more than RMB3.3 billion Series A financing of Shanghai United Imaging Healthcare (now listed on SSE STAR Market: 688271);
- Represented Boyu in its minority equity investment in Hygeia Healthcare (now listed on HKEx; HKEX: 6078).